|
GALT | Galectin Therapeutics Inc |
|
|
GALT | Galectin Therapeutics Inc |
| Pharmaceutical Preparations |
| Book value per $ invested | $ -0.32 |
| Leverage | 1060.59% |
| Market Cap | $ 381.0m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -37.2m |
| Margin | 457.09% |
Galectin Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to the research and development of therapies for fibrotic, cancerous and other diseases. The company is headquartered in Norcross, Georgia.